2025-523157-34-00招募中3 期
A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome
UCB Biosciences Inc.29 个研究点 分布在 7 个国家目标入组 82 人开始时间: 2026年3月31日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 82
- 试验地点
- 29
- 主要终点
- Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score
研究概览
简要总结
To investigate the efficacy of fenfluramine HCl versus placebo in study participants with Rett syndrome (RTT)
入排标准
- 年龄范围
- 0 years 至 64 years（18-64 Years, 0-17 Years）
- 接受健康志愿者
- 否
入选标准
- •Participant has typical or classic Rett Syndrome (RTT) according to the RettSearch Consortium 2010 revised criteria
- •Participant has a documented disease-causing mutation in the methyl-CpG-binding protein 2 (MECP2) gene
- •Participant meets criteria for postregression for at least 6 months prior to Screening, defined as: − No loss or degradation of ambulation (including gait, coordination, or independence of walking/standing); − No loss or degradation of hand function; no loss or degradation of speech (including babbling, words, or previously developed communicative vocalizations); − No loss or degradation of nonverbal communicative or social skills (including eye gaze, using body to indicate communicative intent, or social attentiveness)
- •Participant has an Rett Syndrome Clinical Severity Scale (RTT-CSS) rating of 10 to 36 (inclusive)
- •Participant has a Clinical Global Impression-Severity (CGIS) score of ≥4
- •Participant has a legal representative capable of providing signed informed consent on behalf of the participant as described in the protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol.
- •Participant is aged 5 to 35 years of age (inclusive) at the time of first administration of investigational intervention.
- •Male or female.
- •Participant has a consistent caregiver who is ≥18 years of age at the Screening Visit. The caregiver needs to be able to complete the caregiver assessments defined for the entire study. Every attempt should be made to have the same evaluator complete the assessments for the duration of the study.
排除标准
- •Participant has a history of lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
- •Participant has clinically significant abnormality in vital signs according to the Investigator
- •Participant has an exclusionary cardiovascular or cardiopulmonary abnormality based on echocardiogram (ECHO), electrocardiogram (ECG), or physical examination, and is not approved for entry by the central cardiac reader. Exclusionary abnormalities include, but are not limited to: a. Greater than trace aortic valve regurgitation. b. Greater than mild mitral valve regurgitation. c. Possible signs of pulmonary arterial hypertension (PAH) with abnormal pulmonary artery systolic pressure (PASP) or PASP ≥35 mmHg. d. Evidence of left ventricular dysfunction (systolic or diastolic). e. Clinically significant structural cardiac abnormality, including but not limited to mitral valve prolapse, atrial or ventricular septal defects, or patent ductus arteriosus with reversal of shunt (right to left shunt). Note: Patent foramen ovale without a reversal of shunt or a bicuspid aortic valve is not considered exclusionary
- •Participant has a clinically significant medical condition, including chronic obstructive pulmonary disease, interstitial lung disease, portal hypertension, or need for invasive mechanical ventilation (eg, via tracheostomy), or has had clinically relevant symptoms or a clinically significant illness currently or in the 4 weeks prior to the Screening Visit that would negatively impact study participation, collection of study data, or pose a risk to the participant
- •Participant is taking >4 concomitant antiseizure medications (ASMs). Rescue medications are not included in the count
研究组 & 干预措施
Fintepla 2.2 mg/ml oral solution
Test
干预措施: Fintepla 2.2 mg/ml oral solution (Drug)
Placebo matching < UCB PRODUCT (ZX008, fenfluramine hydrochloride oral solution) > and without active substance
Placebo
干预措施: Placebo matching < UCB PRODUCT (ZX008, fenfluramine hydrochloride oral solution) > and without active substance (Drug)
结局指标
主要结局
Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score
Change from Baseline to Week 14 in Rett Syndrome Behaviour Questionnaire (RSBQ) Total Score
Clinical Global Impression of Change (CGIC) Score at Week 14
Clinical Global Impression of Change (CGIC) Score at Week 14
次要结局
- Incidence of serious TEAEs
- Change from Baseline to Week 14 in Patient-Reported Outcomes Measurement Information System-Sleep Disturbance (PROMIS-SD) score
- Change from Baseline to Week 14 in Observer-Reported Communication Ability (ORCA) score
- Caregiver Global Impression of Change – Seizure (CaGIC-Seizure) score at Week 14
- Incidence of Treatment-emergent adverse event (TEAEs)
- Incidence of TEAEs leading to discontinuation
- Incidence of related TEAEs
- Change from Baseline in QT interval corrected using Fridericia’s formula (QTcF) interval on 12-lead ECG at Week 14
- Treatment-emergent Doppler Echocardiogram (ECHO) results meeting the Food and Drug Administration (FDA) case definition of drug-associated valvular heart disease (VHD)
- Treatment-emergent Doppler ECHO results meeting the FDA case definition of pulmonary arterial hypertension (PAH) >35mmHg
研究者
UCB Cares
Scientific
UCB Biosciences Inc.
研究点 (29)
Loading locations...
相似试验
招募中
2 期
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHNCT07335601Madrigal Pharmaceuticals, Inc.120
尚未招募
3 期
Clinical Study to evaluate the Efficacy and Safety of a Dose for Soreness in reducing Muscle Soreness and improving muscle relaxationCTRI/2024/05/068070Eetho Brands70
招募中
3 期
Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor DeficiencyNCT07266805Pharvaris Netherlands B.V.32
招募中
4 期
A study to assess the effect of Glucocil® on metabolic health in individuals with prediabetes and Type 2 Diabetes MellitusPrediabetesCTRI/2024/07/071682Vedic Lifesciences Pvt. Ltd100
已完成
2 期
A study to assess the effect of Doctor’s Biome Medical Food (DBMF) in individuals with Clostridium difficile infection (CDI)CTRI/2024/06/068931Vedic Lifesciences Pvt. Ltd20